Deutsch
A A A
DE
Bereichsnavigation

Previous
Corporate News | 05/08/2024

RHÖN-KLINIKUM AG starts financial year 2024 with a good first quarter

EQS-News: RHÖN-KLINIKUM Aktiengesellschaft / Key word(s): Quarter Results/Quarter ResultsRHÖN-KLINIKUM AG starts financial year 2024 with a good first quarter 08.05.2024 / 08:59 CET/CESTThe issuer is solely responsible for the content of this announcement.

Corporate News  Bad Neustadt a. d. Saale | 8 May 2024

RHÖN-KLINIKUM AG starts financial year 2024 with a good first quarter

 

RHÖN-KLINIKUM AG, one of the leading healthcare providers in Germany, has made a solid start to financial year 2024. Both consolidated profit and EBITDA as well as revenues rose in the first three months.

Revenues increased by 5.9% to €382.8 million (Q1 2023:  €361.5 million). At €25.2 million, EBITDA (earnings before interest, taxes, depreciation and amortisation) was 12% higher than the previous year (Q1 2023: €22.5 million). Taking into account depreciation, amortisation, financing costs and taxes, EBITDA resulted in a consolidated profit of €11.1 million (Q1 2023: €6.4 million). From January to March 2024, 234,151 outpatients and inpatients were treated in the Group's hospitals and medical care centers (Q1 2023: 228,189).

“RHÖN-KLINIKUM AG considers itself well prepared for the forthcoming hospital reform with positioning of its hospitals. With our RHÖN Campus concept, the growing range of outpatient treatment services and the establishment of new medical services, we are seizing opportunities that we will implement for the benefit of our patients”, says Prof. Dr Tobias Kaltenbach, Chairman of the Board of Management of RHÖN-KLINIKUM AG.

Outlook for 2024 confirmed

For the coming financial year, RHÖN-KLINIKUM AG expects revenues of €1.6 billion euros within a range of +/- 5% upwards and downwards respectively. For earnings before interest, tax and depreciation and amortisation (EBITDA), a level of between €110 million euros and €120 million is expected.

This outlook reflects the further tightening of regulatory intervention by the legislator. RHÖN-KLINIKUM AG points out that the outlook is subject to considerable uncertainties in connection with the numerous global crises resulting in inflation and price increases and subject to any regulatory intervention causing the remuneration structure in 2024.

Quarterly Statement – Q1 2024

 

RHÖN-KLINIKUM AG is one of the leading healthcare providers in Germany. The hospitals offer excellent medical care with a direct tie-in to universities and research facilities. Each year some 882,000 patients are treated at our five sites – RHÖN-KLINIKUM Campus Bad Neustadt, Klinikum Frankfurt (Oder), Universitätsklinikum Gießen and Universitätsklinikum Marburg (UKGM) as well as Zentralklinik Bad Berka. The Company employs over 18,200 persons. The innovative RHÖN Campus approach committed to cross-sector and future-oriented healthcare delivery in rural areas, the steadfast continuation of the gradual digital transformation within the Company as well as the strategic partnership with Asklepios are key elements of our corporate strategy. RHÖN-KLINIKUM AG is an independent Company operating under the umbrella of Asklepios Kliniken GmbH & Co. KGaA. www.rhoen-klinikum-ag.com

Contact:

RHÖN-KLINIKUM AG |Head of Corporate Finance, Treasury, Investor Relations and SustainabilityJulian Schmitt T. +49 9771 65-12250 | julian.schmitt(at)rhoen-klinikum-ag.com

RHÖN-KLINIKUM AG | Schlossplatz 1 | D-97616 Bad Neustadt a. d. Saale


08.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at www.eqs-news.com


Language: English
Company: RHÖN-KLINIKUM Aktiengesellschaft
Salzburger Leite 1
97616 Bad Neustadt a.d.Saale
Germany
Phone: +49 (0)9771 - 65-0
Fax: +49 (0)9771 - 97 467
E-mail: rka@rhoen-klinikum-ag.com
Internet: www.rhoen-klinikum-ag.com
ISIN: DE0007042301
WKN: 704230
Listed: Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange
EQS News ID: 1898205
 
End of News EQS News Service